Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onartuzumab - Genentech

Drug Profile

Onartuzumab - Genentech

Alternative Names: 5D5; anti-c-Met monoclonal antibody - Genentech; hOA-5D5.v2; MetMAb; OA-5D5; PRO-143966; RG-3638; RO-5490258

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 19 Jul 2018 Roche completes a phase III extension trial for Solid tumours in Latvia, Spain, France, Russia, Italy, Japan, Serbia and South Africa (NCT02488330)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2016 Genentech completes a phase II trial in Breast cancer (First-line therapy, second-line therapy or greater, metastatic disease, combination therapy) in USA, Belgium, France, Germany, Spain and United Kingdom (IV) (NCT01186991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top